Decreased PPARγ phosphorylation and increased PPARγ expression induced by PP treatments was responsible for preventing hypoadiponectinemia, thereby allowing adequate adiponectin signaling (increased β-oxidation, insulin sensitivity and glucose uptake; decreased gluconeogenesis). The gene discussed is PPARG; the disease is adiponectin deficiency.